Company: EDSA
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001171843-25-002028
Chunk: 42

Company: Edesa Biotech, Inc.
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 42
---
 Compensation” column of the Summary Compensation Table above.

Other than the funds contributed under our 401(k) plan, no other funds were set aside or accrued by us during the years ended September 30, 2023 and 2022 to provide pension, retirement or similar benefits for our named executive officers.

<div align='center'>EQUITY COMPENSATION PLAN INFORMATION</div>

The following table provides certain information as of September 30, 2024 about our common shares that may be issued under our equity compensation plans, which consists of our 2019 Plan in effect at September 30, 2024:

| Plan Category                                              |     | Number of securities to be issued upon exercise of outstanding options and rights 
 (a)                                                                               |         |     | Weighted-average exercise price of outstanding options and rights 
 (b)                                                               |       |     | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) 
 (c)                                                                                                                                         |         |
|:-----------------------------------------------------------|:----|:----------------------------------------------------------------------------------|--------:|:----|:------------------------------------------------------------------|------:|:----|:--------------------------------------------------------------------------------------------------------------------------------------------|--------:|
| Equity compensation plans approved by security holders     |     |                                                                                   | 459,801 |     | $                                                                 | 24.93 |     |                                                                                                                                             | 141,099 |
| Equity compensation plans not approved by security holders |     |                                                                                   |     N/A |     |                                                                   |   N/A |     |                                                                                                                                             |     N/A |
| Total                                                      |     |                                                                                   | 459,801 |     | $                                                                 | 24.93 |     |                                                                                                                                             | 141,099 |

| (1) | Includes 383,080 common shares issuable upon the exercise of outstanding options and 76,761 common shares issuable upon the conversion of outstanding RSUs. |
| (2) | The weighted-average exercise price does not consider shares issuable upon the conversion of outstanding RSUs, which have no exercise price.                |

Warrants and other equity held by directors, officers and employees outside of the compensation plans are not included in the table above.

<div align='center'>25

REPORT OF THE AUDIT COMMITTEE*</div>

The undersigned members of the Audit Committee of the Board of Edesa Biotech, Inc. (the “Company”) submit this report in connection with the committee’s review of the financial reports for the fiscal year ended September 30, 202